Impact of adjuvant therapy on resected invasive intraductal papillary mucinous neoplasm of the pancreas: a Korean nationwide study
Abstract
Adjuvant therapy (AT) has demonstrated survival benefits in patients with pancreatic ductal adenocarcinoma (PDAC). However, the oncologic efficacy of AT in resected invasive intraductal papillary mucinous neoplasms (IPMN) remains unclear, and there are no established guidelines in this context.
We retrospectively analyzed 539 patients with invasive pancreatic IPMN treated between 2005 and 2020 across 18 centers in Korea. Propensity score-matched (PSM) and stage-matched survival analyses were performed.
A total of 354 patients were enrolled in a 1:1 PSM analysis. Multivariate analysis identified perineural invasion (HR, 2.589; 95% CI, 1.528–4.385;
P
37 (HR, 2.032; 95% CI, 1.227–3.364;
P
< 0.001) as adverse prognostic factors for resected invasive IPMN. In the overall cohort, there were no significant differences in disease-free survival (DFS) and overall survival (OS) between the surgery-alone (SA) and AT groups (
P
= 0.882;
P
= 0.080). Similarly, in the stage-matched analysis, no significant difference in OS was observed between the SA and AT groups (stage I,
P
= 0.621; stage II,
P
= 0.662; stage III,
P
= 0.571). While DFS was improved in the stage I group compared to the SA group (
P
= 0.020), this benefit was not observed in other stages.
Unlike in PDAC, AT was not associated with an OS benefit for resected invasive IPMN across stages I–III. While its efficacy in patients with poor prognostic factors remains uncertain, further prospective studies are warranted to clarify…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 539 participants or records.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.